Immunocore (IMCR) Reports Q3 Earnings: What Key Metrics Have to Say

Core Insights - Immunocore Holdings PLC reported a revenue of $103.69 million for the quarter ended September 2025, reflecting a year-over-year increase of 29.2% [1] - The earnings per share (EPS) was reported at $0, a decrease from $0.17 in the same quarter last year, with a significant EPS surprise of +100% compared to the consensus estimate of -$0.30 [1] Revenue Performance - The revenue from the United States was $67.3 million, surpassing the average estimate of $66.05 million, marking a year-over-year increase of 17.5% [4] - International revenue reached $2.87 million, significantly exceeding the average estimate of $0.98 million, with a year-over-year growth of 52.3% [4] - Revenue from Europe was reported at $33.53 million, slightly below the average estimate of $35.38 million, but still showing a substantial year-over-year increase of 58.9% [4] Stock Performance - Over the past month, Immunocore's shares have declined by 9.4%, while the Zacks S&P 500 composite has increased by 1.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]